Aladdin Healthcare Technologies SE (ALDNF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aladdin Healthcare Technologies SE (ALDNF), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 44/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 18 Mar 2026Aladdin Healthcare Technologies SE (ALDNF) Sağlık ve Boru Hattı Genel Bakışı
Aladdin Healthcare Technologies SE, based in Germany, develops AI and blockchain-based healthcare solutions, including platforms for early disease diagnosis, risk assessment, and drug discovery. Operating in the healthcare information services sector, the company targets chronic diseases using advanced predictive data analytics.
Yatırım Tezi
Aladdin Healthcare Technologies SE presents a speculative investment opportunity within the healthcare information services sector. The company's focus on AI and blockchain technologies for early disease diagnosis and drug discovery could drive future growth, although the company's small size and OTC listing present significant risks. Key value drivers include successful development and commercialization of its AI-powered platforms, particularly the Early Diagnosis and Drug Discovery platforms. Upcoming catalysts include potential partnerships with healthcare providers and pharmaceutical companies to deploy its technologies. However, investors should be aware of the risks associated with OTC-listed companies, including limited liquidity and disclosure.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Aladdin Healthcare Technologies SE operates in the healthcare information services sector, focusing on AI and blockchain technologies.
- The company's P/E ratio is -0.22, reflecting its current lack of profitability.
- Aladdin Healthcare Technologies SE has a beta of 0.55, indicating lower volatility compared to the market.
- The company develops AI-powered platforms for early disease diagnosis, health risk assessment, and drug discovery.
- Aladdin Healthcare Technologies SE employs 3 people, reflecting its small scale of operations.
Rakipler & Benzerleri
Güçlü Yönler
- Innovative AI-powered platforms for early disease diagnosis.
- Secure data management using blockchain technology.
- Focus on addressing chronic diseases with high prevalence.
- Potential for partnerships with healthcare providers and pharmaceutical companies.
Zayıflıklar
- Small company size and limited resources.
- Dependence on successful development and commercialization of new technologies.
- Limited operating history and track record.
- OTC listing with associated liquidity and disclosure risks.
Katalizörler
- Upcoming: Potential partnerships with healthcare providers to implement AI diagnostic platforms.
- Upcoming: Development and launch of new AI-powered healthcare solutions.
- Ongoing: Continued research and development in AI-assisted drug discovery.
- Ongoing: Expansion of blockchain technology for secure data management.
Riskler
- Potential: Intense competition from larger healthcare technology companies.
- Potential: Regulatory hurdles and compliance requirements in the healthcare industry.
- Potential: Data security and privacy concerns related to patient information.
- Ongoing: Limited liquidity and high volatility due to OTC listing.
Büyüme Fırsatları
- Expansion of AI-Powered Diagnostic Platforms: Aladdin Healthcare Technologies SE has the opportunity to expand its AI-powered diagnostic platforms for early disease detection. The global AI in healthcare market is projected to reach $95 billion by 2030, offering a substantial market for Aladdin's AI Early Diagnosis platform. Successful development and deployment of these platforms could drive significant revenue growth.
- Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with hospitals, clinics, and other healthcare providers can accelerate the adoption of Aladdin's technologies. These partnerships can provide access to larger patient populations and facilitate the integration of Aladdin's platforms into existing healthcare workflows. Successful partnerships could lead to recurring revenue streams and increased market penetration.
- Drug Discovery Platform Commercialization: Aladdin's AI-assisted Drug Discovery platform presents a significant growth opportunity. The global drug discovery market is expected to reach $81.3 billion by 2028. By identifying promising drug candidates for age-related diseases, Aladdin can generate revenue through licensing agreements or the development of its own drug pipeline.
- Geographic Expansion into New Markets: Aladdin Healthcare Technologies SE can expand its operations into new geographic markets, particularly in regions with growing healthcare expenditures and increasing adoption of digital health technologies. Emerging markets in Asia and Latin America offer significant growth potential for Aladdin's AI and blockchain-based solutions. Expansion into these markets can diversify revenue streams and reduce reliance on the European market.
- Integration of Blockchain for Data Security: Leveraging blockchain technology to enhance data security and privacy can attract healthcare providers and patients concerned about data breaches and regulatory compliance. The blockchain in healthcare market is projected to reach $1.6 billion by 2027. By offering secure and transparent data management solutions, Aladdin can differentiate itself from competitors and gain a competitive advantage.
Fırsatlar
- Expanding into new geographic markets with growing healthcare expenditures.
- Forming strategic alliances with hospitals and research institutions.
- Leveraging AI and machine learning to enhance drug discovery.
- Capitalizing on the increasing adoption of digital health solutions.
Tehditler
- Intense competition from larger and more established healthcare technology companies.
- Regulatory hurdles and compliance requirements in the healthcare industry.
- Data security and privacy concerns related to patient information.
- Potential for technological obsolescence and disruption.
Rekabet Avantajları
- Proprietary AI algorithms for early disease diagnosis.
- Blockchain technology for secure and transparent data management.
- Expertise in healthcare data analytics and machine learning.
- Strategic partnerships with healthcare providers and research institutions.
ALDNF Hakkında
Founded in 2014 and headquartered in Berlin, Germany, Aladdin Healthcare Technologies SE operates through its subsidiary, Aladdin Healthcare Technologies Ltd, focusing on the intersection of healthcare and advanced technology. The company develops software solutions for health information storage and management, leveraging blockchain technology to ensure data security and integrity. Aladdin specializes in technologies such as blockchain, machine learning, and artificial intelligence to create innovative healthcare platforms. Its core offerings include the Artificial Intelligence Early Diagnosis platform, designed for brain imaging analysis, the Health Risk Assessment platform, which assesses the risk of cardiovascular, diabetes, and kidney-related diseases, and the Artificial Intelligence assisted Drug Discovery platform, aimed at identifying small molecule drug compounds for age-related diseases like Alzheimer's, Parkinson's, and SARS-CoV-2. By using blockchain, machine learning, AI, and advanced predictive data analytics, Aladdin aims to facilitate the early diagnosis of chronic diseases, improving patient outcomes and reducing healthcare costs. The company's focus on AI and blockchain positions it as a player in the evolving landscape of healthcare technology.
Ne Yaparlar
- Develops software solutions for health information storage and management.
- Utilizes blockchain technology for secure data handling.
- Specializes in artificial intelligence and machine learning applications in healthcare.
- Creates AI-powered platforms for early disease diagnosis.
- Offers health risk assessment tools for cardiovascular, diabetes, and kidney-related diseases.
- Develops AI-assisted drug discovery platforms for age-related diseases.
İş Modeli
- Develops and licenses AI-powered healthcare platforms to hospitals and clinics.
- Generates revenue through software subscriptions and licensing fees.
- Partners with pharmaceutical companies for drug discovery and development.
- Provides data analytics services to healthcare providers.
Sektör Bağlamı
Aladdin Healthcare Technologies SE operates within the healthcare information services industry, a sector experiencing rapid growth due to the increasing adoption of digital health solutions and the need for efficient data management. The market is driven by factors such as the rising prevalence of chronic diseases, the growing demand for personalized medicine, and advancements in AI and machine learning. Competitors include companies like Applied Therapeutics Inc (APTCF), and MedMira Inc (MMNFF). Aladdin's focus on blockchain and AI differentiates it within this competitive landscape.
Kilit Müşteriler
- Hospitals and clinics seeking to improve diagnostic accuracy and efficiency.
- Pharmaceutical companies looking for AI-driven drug discovery solutions.
- Healthcare providers aiming to enhance patient risk assessment and management.
- Research institutions interested in AI-based healthcare data analysis.
Finansallar
Grafik & Bilgi
Aladdin Healthcare Technologies SE (ALDNF) hisse senedi fiyatı: Price data unavailable
Son Haberler
ALDNF için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
ALDNF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
ALDNF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, ALDNF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Wade Menpes-Smith
Managing Director
Wade Menpes-Smith serves as the Managing Director of Aladdin Healthcare Technologies SE. His background includes experience in managing small teams and overseeing the development of technology solutions. His leadership is focused on driving the company's strategic initiatives in AI and blockchain-based healthcare solutions. He is responsible for guiding the company's research and development efforts and fostering partnerships with healthcare providers and pharmaceutical companies.
Sicil: Under Wade Menpes-Smith's leadership, Aladdin Healthcare Technologies SE has focused on developing its AI-powered platforms for early disease diagnosis and drug discovery. He has overseen the company's efforts to leverage blockchain technology for secure data management and has worked to establish partnerships to expand the reach of Aladdin's solutions. Given the company's small size, his role is critical in shaping its strategic direction.
ALDNF OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aladdin Healthcare Technologies SE may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited liquidity due to OTC Other listing.
- Lack of regulatory oversight and potential for fraud or manipulation.
- Inconsistent or limited financial reporting.
- High price volatility and potential for significant losses.
- Dependence on successful development and commercialization of new technologies.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's competitive position and market opportunities.
- Evaluate the company's technology and intellectual property.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Focus on AI and blockchain technologies in healthcare.
- Development of AI-powered platforms for early disease diagnosis.
- Partnerships with healthcare providers and research institutions (if any).
- Presence of a management team with relevant experience.
Aladdin Healthcare Technologies SE Hissesi: Cevaplanan Temel Sorular
ALDNF için değerlendirilmesi gereken temel faktörler nelerdir?
Aladdin Healthcare Technologies SE (ALDNF) şu anda yapay zeka skoru 44/100, düşük puanı gösteriyor. Temel güçlü yan: Innovative AI-powered platforms for early disease diagnosis.. İzlenmesi gereken birincil risk: Potential: Intense competition from larger healthcare technology companies.. Bu bir finansal tavsiye değildir.
ALDNF MoonshotScore'u nedir?
ALDNF şu anda MoonshotScore'da 44/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
ALDNF verileri ne sıklıkla güncellenir?
ALDNF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler ALDNF hakkında ne diyor?
ALDNF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
ALDNF'a yatırım yapmanın riskleri nelerdir?
ALDNF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Intense competition from larger healthcare technology companies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
ALDNF'ın P/E oranı nedir?
ALDNF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için ALDNF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
ALDNF aşırı değerli mi, yoksa düşük değerli mi?
Aladdin Healthcare Technologies SE (ALDNF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
ALDNF'ın temettü verimi nedir?
Aladdin Healthcare Technologies SE (ALDNF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Information is based on publicly available sources and may be limited due to the company's OTC listing and limited disclosure.